These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3960261)

  • 21. [Idiopathic calcium nephrolithiasis: therapeutic aspects].
    Jaeger P; Portmann L; Burckhardt P
    Schweiz Med Wochenschr; 1983 Nov; 113(47):1750-6. PubMed ID: 6658421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The prevention of recurrence of calculus: results of a regional study].
    Labeeuw M; Pozet N; Martin X; Lareal MC
    Nephrologie; 1989; 10(4):205-7. PubMed ID: 2633068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of thiazide therapy in the prophylaxis of calcium lithiasis].
    Fernández Rodríguez A; Arrabal Martín M; García Ruiz MJ; De Haro Muñoz T; Zuluaga Gómez A
    Arch Esp Urol; 2001 Nov; 54(9):1047-54. PubMed ID: 11789362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative study of urinary calcium, oxalate and uric acid in calcium oxalate lithiasis].
    Dumoulin G; Haton D; Wolf JP; Henriet MT; Nguyen NU; Mougin C; Saint-Hillier Y; Combes M; Berthelay S
    Nephrologie; 1984; 5(5):189-91. PubMed ID: 6531054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium-uric acid nephrolithiasis.
    Coe FL
    Arch Intern Med; 1978 Jul; 138(7):1090-3. PubMed ID: 666467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism.
    Parks JH; Coe FL; Evan AP; Worcester EM
    BJU Int; 2009 Mar; 103(5):670-8. PubMed ID: 18793297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of allopurinol in the prevention of calcium oxalate calculi.
    Ettinger B; Tang A; Citron JT; Livermore B; Williams T
    N Engl J Med; 1986 Nov; 315(22):1386-9. PubMed ID: 3534570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical evaluation of various forms of therapy for idiopathic calcium stone disease.
    Marangella M; Tricerri A; Sonego S; Ronzani M; Fruttero B; Daniele PG; Bruno M; Linari F
    Proc Eur Dial Transplant Assoc; 1983; 20():434-9. PubMed ID: 6361754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prevention of urinary calculi with thiazides and allopurinol. A long-term study].
    May P; Pilorz H; Duhme C; Pöpperl H; Braun J
    Urologe A; 1984 Mar; 23(2):87-90. PubMed ID: 6426113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion.
    Domrongkitchaiporn S; Stitchantrakul W; Kochakarn W
    Am J Kidney Dis; 2006 Oct; 48(4):546-54. PubMed ID: 16997050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of renal excretion of uric acid during long-term thiazide therapy.
    Pak CY; Tolentino R; Stewart A; Galosy RA
    Invest Urol; 1978 Nov; 16(3):191-3. PubMed ID: 711411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Studies of urinary risk factors in urolithiasis].
    Ebisuno S; Kitagawa M; Morimoto S; Miyazaki Y; Minakata S; Yasukawa S; Fukatani T; Ohkawa T
    Hinyokika Kiyo; 1985 Jan; 31(1):1-15. PubMed ID: 3993484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Etiopathogenesis and clinical aspects of nephrolithiasis--at present].
    Ferrari L; Meschi M; Musini S; Frattini A; Savazzi GM
    Recenti Prog Med; 2003 Mar; 94(3):136-41. PubMed ID: 12677782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hydrochlorothiazide, allopurinol and magnesium oxide in the treatment of recurrent calcium urolithiasis].
    Musialik D; Głuszek J; Pieczyńska A
    Pol Tyg Lek; 1991 Oct 7-21; 46(40-42):739-42. PubMed ID: 1669148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Castaldo R; Manno G; Guadagno V; Strazzullo P; Nunziata V
    Urology; 2004 Oct; 64(4):833-8. PubMed ID: 15491743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Physiopathology, exploration and treatment of calcium lithiasis].
    Bataille P; Achard JM; Fournier A
    Rev Prat; 1991 Oct; 41(21):2024-36. PubMed ID: 1784895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The preventive effect of sodium pentosan polysulfate against renal stone formation in hyperoxaluric rats.
    Nakatani T; Ishii K; Yoneda Y; Kamikawa S; Kanazawa T; Sugimoto T; Osswald H
    Urol Res; 2002 Oct; 30(5):329-35. PubMed ID: 12389123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diets with either beef or plant proteins reduce risk of calcium oxalate precipitation in patients with a history of calcium kidney stones.
    Massey LK; Kynast-Gales SA
    J Am Diet Assoc; 2001 Mar; 101(3):326-31. PubMed ID: 11269613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.